Craig Beeson to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Craig Beeson has written about Xenograft Model Antitumor Assays.
Connection Strength
0.271
-
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res. 2019 02 01; 25(3):1036-1049.
Score: 0.141
-
Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates. Bioconjug Chem. 2003 Sep-Oct; 14(5):927-33.
Score: 0.049
-
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nat Commun. 2019 03 21; 10(1):1296.
Score: 0.036
-
LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J Pharmacol Exp Ther. 2013 Jan; 344(1):167-78.
Score: 0.023
-
Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells. Int J Cancer. 2012 Feb 01; 130(3):532-43.
Score: 0.021